Overview

* Jazz Pharmaceuticals ( JAZZ ) Q2 rev rises 2%

* Adjusted EPS for Q2 misses consensus, impacted by Chimerix acquisition expenses

* Co repurchased shares worth $125 mln, part of $500 mln authorization

Outlook

* Jazz Pharmaceuticals ( JAZZ ) updates 2025 revenue guidance to $4.15-$4.30 bln

* Company expects multiple oncology catalysts to drive revenue growth

* Jazz Pharmaceuticals ( JAZZ ) anticipates blockbuster status for Epidiolex in 2025

* Company projects improved effective tax rate for 2025

Result Drivers

* XYWAV GROWTH - Xywav revenues grew 13% year-over-year, driven by net patient additions of 625

* ZEPZELCA DECLINE - Zepzelca sales fell 8% due to increased competition and treatment protocol updates

* CHIMERIX IMPACT - Acquisition of Chimerix contributed to adjusted EPS miss due to associated expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $1.05 $1.05

Revenue bln bln (16

Analysts

)

Q2 Miss -$8.25 -$7.61

Adjusted (14

EPS Analysts

)

Q2 EPS -$11.74

Q2 Miss -$504.85 -$459.90

Adjusted mln mln (12

Net Analysts

Income )

Q2 Net -$718.47

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC ( JAZZ ) is $178.21, about 34.9% above its August 4 closing price of $116.10

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)